89bio, Inc/$ETNB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About 89bio, Inc

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

Ticker

$ETNB
Primary listing

Industry

Biotechnology

Employees

93

ISIN

US2825591033

89bio, Inc Metrics

BasicAdvanced
$1.5B
-
-$3.30
1.29
-

What the Analysts think about 89bio, Inc

Analyst ratings (Buy, Hold, Sell) for 89bio, Inc stock.

Bulls say / Bears say

Analysts have assigned 89bio a consensus 'Moderate Buy' rating with an average 12-month price target of $30.33, indicating potential upside from current levels. (americanbankingnews.com)
In January 2025, 89bio successfully raised approximately $287.5 million through a public offering, bolstering its financial position to support ongoing clinical trials and operations. (stocktitan.net)
Director Ra Capital Management, L.P. significantly increased its stake by purchasing 5,714,285 shares at $8.75 each in January 2025, reflecting strong insider confidence in the company's prospects. (insidertrades.com)
In January 2025, insider Quoc Le-Nguyen sold 10,963 shares at an average price of $6.49, which could be interpreted as a lack of confidence in the company's short-term performance. (mayfieldrecorder.com)
89bio reported a quarterly loss of $1.02 per share in March 2025, missing analysts' consensus estimates of a $0.60 loss, raising concerns about the company's financial health. (defenseworld.net)
The company's stock price has experienced significant volatility, with a 12-month range between $5.99 and $16.63, which may deter risk-averse investors. (etfdailynews.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.

89bio, Inc Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

89bio, Inc Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ETNB

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs